Oral salmon calcitonin: Phase III ongoing

Emisphere said a futility analysis of 1-year data prompted an independent DMC to recommend stopping the Phase III Study 2302 of oral salmon calcitonin to treat OA of the knee for efficacy reasons. Novartis, along with development partner Nordic, will continue the 2-year trial, but declined to provide a reason why. In December, a DMC recommended continuation of the parallel Phase III 2301 trial in the indication. Data from that trial are expected next quarter. ...